Serplulimab

Serplulimab (HLX10, brand name Hansizhuang) is Shanghai Henlius Biotech's anti-PD-1 antibody, approved in China since 2022 for MSI-H solid tumors and 2023 for first-line extensive-stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy [1][2]. Outside China it remains investigational, with active Phase II studies in cervical cancer, gastric cancer, NSCLC, renal cell carcinoma, pancreatic cancer, and triple-negative breast cancer [3][4][5][6][7]. The molecule is a me-too PD-1 inhibitor entering a market dominated by Keytruda - its commercial path West depends on price, combination strategy, and whether Henlius/Fosun can secure approvals in Europe and Southeast Asia before Keytruda's US patent cliff in 2028 erases the price-discount lever [8][9][18].

Approved in China by the NMPA, not the FDA. Hansizhuang launched in 2022 for microsatellite instability-high (MSI-H) solid tumors - tumors with broken DNA repair machinery that produce lots of mutated proteins, making them visible to the immune system [1]. A second NMPA approval came in 2023 for first-line extensive-stage SCLC plus chemotherapy, based on the ASTRUM-005 Phase III which showed an overall survival benefit versus chemo alone [2]. A third NMPA approval followed in September 2023 for first-line PD-L1+ esophageal squamous cell carcinoma (ESCC) on the strength of ASTRUM-007, a Phase III that showed median OS 15.3 vs 11.8 months versus chemo alone, with the benefit enriched in CPS≥10 patients (18.6 vs 13.9 months) [13][19]. A fourth indication in squamous NSCLC followed from ASTRUM-004. Henlius reports the franchise has now treated more than 75,000 patients globally [17]. No FDA designations have been disclosed. The linked Phase III trial NCT06419673 is testing serplulimab plus chemoradiotherapy in FIGO 2018 stage III-IVA cervical cancer; primary completion timing is not posted publicly on ClinicalTrials.gov [10]. Around it sits a sprawling portfolio of Phase II investigator-initiated and company-sponsored studies, including TNBC neoadjuvant (NCT07283692), gastric cancer second-line post-IO - IO meaning prior immunotherapy (NCT05585580), elderly NSCLC monotherapy (NCT07596121), non-clear cell RCC (NCT05831891), and early-relapse colorectal cancer (NCT07604909) [3][4][5][6][7]. The near-term value flow runs through Chinese sales reported via Fosun Pharma, though Fosun does not break out Hansizhuang revenue separately in its 2024 annual report [8].

PD-1 is a brake on T cells. When a T cell gets activated and starts attacking something, it puts PD-1 on its surface. Tumor cells learn to display PD-L1, which presses that brake and tells the T cell to stand down [11]. Anti-PD-1 antibodies like serplulimab physically block PD-1 from being engaged, releasing the brake so T cells keep attacking. This is the most validated mechanism in oncology - Keytruda (pembrolizumab) alone generated $29.5B in 2024 across more than 40 approved indications [9]. So the biology question for serplulimab isn't whether anti-PD-1 works, but whether this particular antibody does anything Keytruda or Opdivo doesn't. The answer so far is mostly no. ASTRUM-005 was the first Phase III to show OS benefit in first-line extensive-stage SCLC for a PD-1 inhibitor specifically (atezolizumab and durvalumab in this setting are anti-PD-L1, not PD-1), which gives serplulimab a narrow scientific claim [2]. Beyond that distinction, it's a fungible asset in a class where the eighth and ninth entrants compete primarily on price.

NCT06419673 - the node-linked trial - evaluates serplulimab plus chemoradiotherapy versus chemoradiotherapy alone in locally advanced stage III-IVA cervical cancer [10]. KEYNOTE-A18 already showed Keytruda added to chemoradiation improves progression-free survival (PFS - time from randomization to disease progression or death) and overall survival in this exact population, leading to FDA approval in early 2024 [12]. Serplulimab is essentially testing whether it can replicate that benefit, which is a low-novelty hypothesis with high precedent. Three near-term Phase II readouts in the broader program are more interesting: NCT05585580 (gastric cancer second-line after prior IO, n=59, ORR primary - objective response rate, the fraction of patients whose tumor shrinks by ≥30%, active not recruiting at Qilu Hospital) [3], NCT07283692 (Neo-SERPENT - neoadjuvant TNBC with weekly paclitaxel/carboplatin, n=46, pCR primary - pathological complete response, meaning no residual invasive tumor in breast or lymph nodes at surgery, at RenJi Hospital) [4], and NCT07604909 (early-relapse colorectal post-adjuvant chemo, n=40, PFS primary at Fudan) [5]. The TNBC neoadjuvant trial is the most differentiated - KEYNOTE-522 sets a high bar with ~65% pCR in the overall TNBC population (64.8% vs 51.2% placebo); benefit was consistent regardless of PD-L1 status, so a Neo-SERPENT readout in the low-60s would be class-typical rather than differentiated [20]. Trial sizes are small and investigator-initiated, which limits how much regulatory weight any single readout will carry.

The model gives this drug a 4% chance of eventually being approved. That starts from a 13% historical baseline for Phase 2 drugs in this area, then gets adjusted using ten facts about the trial and sponsor. The estimate is pulled down mainly by the sponsor's thin approval record, weak earlier-phase results, and a randomized trial design. One factor helps - enrollment is larger than typical for this phase - but not enough to offset the rest.

Efficacy risk is moderate-low - PD-1 blockade works in these tumor types and serplulimab has shown class-typical activity in earlier studies [14]. The dominant problem is differentiation: every active trial is testing whether serplulimab matches Keytruda or Opdivo in a setting where those drugs are already standard or near-standard. Strong data may not move the commercial needle outside China. Safety risk is class-typical - pneumonitis, hepatitis, colitis, endocrinopathies are on-target immune-mediated adverse events common to all PD-1 inhibitors, and nothing in serplulimab's profile suggests it's safer than competitors [14]. Regulatory risk West is the sleeper issue: no FDA filing has been announced, and the agency has grown skeptical of single-country Chinese oncology data after the sintilimab (Innovent/Lilly) and tislelizumab (BeiGene) experiences for indications where US standard of care has moved [15]. Commercial risk is the most likely failure mode - and the biggest near-term headwind is the Keytruda patent cliff. Pembrolizumab's US composition-of-matter patent expires in 2028, with biosimilar programs from Samsung Bioepis, Amgen, and several Indian manufacturers already in clinical development and FDA filings possible as early as 2026-2027 [18]. If biosimilar Keytruda enters the US market before serplulimab secures FDA approval, the price-competitive me-too positioning collapses. Serplulimab's own composition-of-matter patent timeline has not been publicly disclosed in a verifiable form, but the franchise's defensible window is bounded by the same biosimilar dynamics in major markets. The drug is a Chinese franchise asset, not a global one.

Watch, don't buy. Serplulimab is a competent PD-1 inhibitor with a real Chinese franchise - four NMPA approvals across MSI-H solid tumors, ES-SCLC, ESCC, and squamous NSCLC, more than 75,000 patients treated to date - and a Phase II portfolio that mostly asks whether it can match Keytruda's existing wins [1][2][13][17]. Real signal would be (1) an FDA filing acceptance for any indication - that's the binary event that changes the global story, (2) a Phase III readout in an indication where Keytruda hasn't planted a flag, or (3) a major ex-China licensing deal with a Western partner indicating confidence in the regulatory path. The TNBC neoadjuvant trial Neo-SERPENT (NCT07283692) is the single Phase II most worth tracking - pCR data could create pricing use in emerging markets even without cracking the US [4]. The overhanging concern: the window to monetize a price-discount positioning is closing as Keytruda biosimilars approach the 2028 US patent expiry [18], and Fosun has not separately disclosed Hansizhuang revenue in 2024 results, which limits visibility into franchise momentum [8]. Check back at Fosun Pharma's H1 2026 results for any Hansizhuang-specific disclosure, and watch for 2026 Henlius announcements on European or Southeast Asian regulatory submissions. Until one of those triggers fires, this is a name to monitor in the PD-1 cluster, not a stock thesis.